Evidence map›Paper›PMID 37745517›Full record

ArticlebioRxiv : the preprint server for biology2023

Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants.

Panke Qu, Kai Xu, Julia N Faraone, Negin Goodarzi, Yi-Min Zheng, Claire Carlin, Joseph S Bednash, Jeffrey C Horowitz, Rama K Mallampalli, Linda J Saif and 4 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Development of practical techniques for simultaneous detection and distinction of current and emerging SARS-CoV-2 variants.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2023
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Panke QuCenter for Retrovirus Research, The Ohio State University, Columbus, OH 43210, USA.
Kai XuCenter for Retrovirus Research, The Ohio State University, Columbus, OH 43210, USA.
Julia N FaraoneCenter for Retrovirus Research, The Ohio State University, Columbus, OH 43210, USA.
Negin GoodarziCenter for Retrovirus Research, The Ohio State University, Columbus, OH 43210, USA.
Yi-Min ZhengCenter for Retrovirus Research, The Ohio State University, Columbus, OH 43210, USA.
Claire CarlinDepartment of Internal Medicine, Division of Cardiovascular Medicine, The Ohio State University, Columbus, OH 43210, USA.
Joseph S BednashDepartment of Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, The Ohio State University, Columbus, OH 43210, USA.
Jeffrey C HorowitzDepartment of Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, The Ohio State University, Columbus, OH 43210, USA.
Rama K MallampalliDepartment of Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, The Ohio State University, Columbus, OH 43210, USA.
Linda J SaifCenter for Food Animal Health, Animal Sciences Department, OARDC, College of Food, Agricultural and Environmental Sciences, The Ohio State University, Wooster, OH 44691, USA.
Eugene M OltzDepartment of Microbial Infection and Immunity, The Ohio State University, Columbus, OH 43210, USA.
Daniel JonesDepartment of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Richard J GuminaDepartment of Internal Medicine, Division of Cardiovascular Medicine, The Ohio State University, Columbus, OH 43210, USA.
Shan-Lu LiuCenter for Retrovirus Research, The Ohio State University, Columbus, OH 43210, USA.

Funding

The OSU Center for Clinical and Translational Science: Advancing Today's Discoveries to Improve HealthUL1TR002733 · NCATS · OHIO STATE UNIVERSITY · PI RINGEL, MATTHEW D · 2018 to 2022
$28.9M
Project 3: Responding to Changing Serological and Viral Information around COVID-19 (RESPOND)U54CA260582 · NCI · OHIO STATE UNIVERSITY · PI MCALEARNEY, ANN SCHECK, OLTZ, EUGENE M · 2020 to 2024
$10.4M
Institutional Career Development CoreKL2TR002734 · NCATS · OHIO STATE UNIVERSITY · PI CARNES, CYNTHIA A · 2018 to 2022
$2.7M
The impact of vitamin A on the gut-mammary gland-secretory IgA axis during enteric viral infectionsR01HD095881 · NICHD · OHIO STATE UNIVERSITY · PI SAIF, LINDA J., VLASOVA, ANASTASIA NICKOLAEVNA · 2018 to 2022
$2.3M
NCATS NIH HHS KL2 TR002734NCATS NIH HHS UL1 TR002733NCI NIH HHS U54 CA260582NICHD NIH HHS R01 HD095881
6 · The paper itself

Abstract

Evolution of SARS-CoV-2 requires the reassessment of current vaccine measures. Here, we characterized BA.2.86 and the XBB-lineage variant FLip by investigating their neutralization alongside D614G, BA.1, BA.2, BA.4/5, XBB.1.5, and EG.5.1 by sera from 3-dose vaccinated and bivalent vaccinated healthcare workers, XBB.1.5-wave infected first responders, and monoclonal antibody (mAb) S309. We assessed the biology of the variant Spikes by measuring viral infectivity and membrane fusogenicity. BA.2.86 is less immune evasive compared to FLip and other XBB variants, consistent with antigenic distances. Importantly, distinct from XBB variants, mAb S309 was unable to neutralize BA.2.86, likely due to a D339H mutation based on modeling. BA.2.86 had relatively high fusogenicity and infectivity in CaLu-3 cells but low fusion and infectivity in 293T-ACE2 cells compared to some XBB variants, suggesting a potentially differences conformational stability of BA.2.86 Spike. Overall, our study underscores the importance of SARS-CoV-2 variant surveillance and the need for updated COVID-19 vaccines.

Identifiers

PMID37745517
PMCPMC10515800

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.